2019
Evaluation of the effects on the QT-interval of 4 artemisinin-based combination therapies with a correction-free and heart rate-free method
Funck-Brentano C, Ouologuem N, Duparc S, Felices M, Sirima S, Sagara I, Soulama I, Ouedraogo J, Beavogui A, Borghini-Fuhrer I, Khan Y, Djimdé A, Voiriot P. Evaluation of the effects on the QT-interval of 4 artemisinin-based combination therapies with a correction-free and heart rate-free method. Scientific Reports 2019, 9: 883. PMID: 30696921, PMCID: PMC6351684, DOI: 10.1038/s41598-018-37113-5.Peer-Reviewed Original ResearchConceptsArtemisinin-based combination therapyQTc prolongationHeart rate changesCombination therapyVentricular repolarizationQT/QTc interval prolongationEvidence of proarrhythmiaQTc interval prolongationQTc assessmentLethal ventricular arrhythmiasExtent of prolongationMalaria crisisArtemether-lumefantrineInterval prolongationVentricular arrhythmiasAfrican patientsClinical safetyFirst episodeQT intervalHeart rateAntimalarial drugsProlongationQT correctionECG recordingsHigh-quality ECG recording
2015
Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial
Sagara I, Beavogui A, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, Camara D, Somé A, Coulibaly A, Traore O, Dara N, Kabore M, Thera I, Compaore Y, Sylla M, Nikiema F, Diallo M, Dicko A, Gil J, Borrmann S, Duparc S, Miller R, Doumbo O, Shin J, Bjorkman A, Ouedraogo J, Sirima S, Djimdé A. Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial. The Lancet Infectious Diseases 2015, 16: 189-198. PMID: 26601738, PMCID: PMC4726763, DOI: 10.1016/s1473-3099(15)00318-7.Peer-Reviewed Original ResearchConceptsSubstudy analysisFirst episodeFirst treatmentArtemisinin-based combination treatmentDeveloping Countries Clinical Trials PartnershipPrimary safety endpointPyronaridine-artesunate efficacyHistory of feverIncidence of hepatotoxicityAdverse event frequencyExclusion of patientsUK Medical Research CouncilMedical Research CouncilParasitological responseSafety endpointArtemether-lumefantrineMalaria episodesTreat analysisAfrican patientsMalaria treatmentClinical trialsMalaria VentureLaboratory valuesAlanine aminotransferaseHealth facilitiesGenetic mutations in African patients with atrial fibrillation: Rationale and design of the Study of Genetics of Atrial Fibrillation in an African Population (SIGNAL)
Bloomfield GS, Temu TM, Akwanalo CO, Chen PS, Emonyi W, Heckbert SR, Koech MM, Manji I, Shen C, Vatta M, Velazquez EJ, Wessel J, Kimaiyo S, Inui TS. Genetic mutations in African patients with atrial fibrillation: Rationale and design of the Study of Genetics of Atrial Fibrillation in an African Population (SIGNAL). American Heart Journal 2015, 170: 455-464.e5. PMID: 26385028, PMCID: PMC4575772, DOI: 10.1016/j.ahj.2015.06.008.Peer-Reviewed Original ResearchConceptsValvular atrial fibrillationNonvalvular atrial fibrillationValvular heart diseaseAtrial fibrillationHeart diseaseCurrent tobacco smokingHistory of strokeCase-control studyGroup morbidityGenetic associationTobacco smokingSaharan AfricaMean ageAfrican patientsCardiovascular diseaseClinical phenotypingFibrillationPrimary analysisPatientsControl populationGenetic testingMorbidityDiseaseGenetic mutationsMost participants
2010
HAART and response to therapy improve quality of life (QOL) of African patients with advanced HIV-associated Kaposi’s sarcoma (HIV-KS): a prospective analysis of QOL in the KAART trial
Mosam A, Shaik F, Uldrick T, Esterhuizen T, Friedland G, Scadden D, Aboobaker J, Coovadia H. HAART and response to therapy improve quality of life (QOL) of African patients with advanced HIV-associated Kaposi’s sarcoma (HIV-KS): a prospective analysis of QOL in the KAART trial. Infectious Agents And Cancer 2010, 5: a30. PMCID: PMC3002689, DOI: 10.1186/1750-9378-5-s1-a30.Peer-Reviewed Original Research
2006
Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV
Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. Journal Of Antimicrobial Chemotherapy 2006, 58: 1299-1302. PMID: 17032686, DOI: 10.1093/jac/dkl399.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlkynesAnti-HIV AgentsAntibiotics, AntitubercularBenzoxazinesCD4 Lymphocyte CountChromatography, High Pressure LiquidCyclopropanesDidanosineDrug Therapy, CombinationFemaleHIV InfectionsHumansLamivudineLongitudinal StudiesMaleOxazinesRifampinTreatment OutcomeTuberculosis, PulmonaryViral LoadConceptsExcellent clinical outcomesEfavirenz concentrationsClinical outcomesAntiretroviral therapyEfavirenz levelsAfrican patientsNon-detectable viral loadSmear-positive pulmonary TBLong-term clinical outcomesAdministration of efavirenzCD4 cell increaseHIV clinical outcomesPlasma efavirenz concentrationsCells/mm3Half of patientsTB regimenPulmonary TBPharmacokinetic interactionsTB outcomesTherapy completionRifampicin administrationViral loadTherapeutic rangePatientsHIV
2004
Therapeutic Response of HIV-1 Subtype C in African Patients Coinfected with either Mycobacterium tuberculosis or Human Herpesvirus-8
Cassol E, Page T, Mosam A, Friedland G, Jack C, Lalloo U, Kopetka J, Patterson B, Esterhuizen T, Coovadia HM. Therapeutic Response of HIV-1 Subtype C in African Patients Coinfected with either Mycobacterium tuberculosis or Human Herpesvirus-8. The Journal Of Infectious Diseases 2004, 191: 324-332. PMID: 15633090, DOI: 10.1086/427337.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAIDS-Related Opportunistic InfectionsAnti-HIV AgentsCD4 Lymphocyte CountDrug Therapy, CombinationFemaleHerpesvirus 8, HumanHIV InfectionsHIV-1HumansMaleMiddle AgedMycobacterium tuberculosisReverse Transcriptase InhibitorsRNA, ViralSarcoma, KaposiTreatment OutcomeTuberculosis, PulmonaryViral LoadConceptsKaposi's sarcomaHIV-1Opportunistic infectionsViral loadAfrican patientsUndetectable HIV-1 RNA levelsCell countHIV-1 RNA levelsPlasma HIV-1 levelsHuman immunodeficiency virus (HIV) infectionHIV-1 subtype CKaplan-Meier survival analysisMycobacterium tuberculosisHIV-1 levelsImmunodeficiency virus infectionProportion of patientsTarget cell availabilityHuman herpesvirus 8Immune activationTreatment regimensSubtype CTherapeutic responseTreatment outcomesVirus infectionHerpesvirus 8
1985
Antibody Responses to Two Epstein-Barr Virus Nuclear Antigens Defined by Gene Transfer
Miller G, Grogan E, Fischer D, Niederman J, Schooley R, Henle W, Lenoir G, Liu C. Antibody Responses to Two Epstein-Barr Virus Nuclear Antigens Defined by Gene Transfer. New England Journal Of Medicine 1985, 312: 750-755. PMID: 2983211, DOI: 10.1056/nejm198503213121204.Peer-Reviewed Original ResearchConceptsChronic active EBV infectionActive EBV infectionEBV infectionNuclear antigenEpstein-Barr virus nuclear antigenEpstein-Barr virus DNAEBV-seropositive subjectsAbnormal immune responseAssociation of EBVNorth African patientsAbsence of antibodiesSuch patientsAfrican patientsSerologic studiesImmune responseNasopharyngeal carcinomaLymphoid cellsPatientsViral gene productsSpecific viral gene productsViral mutationsSerologic reactionsAntigenSerum samplesM antigen
1975
The American Burkitt Lymphoma Registry: a progress report.
Levine P, Connelly R, Berard C, O'Connor G, Dorfman R, EASTON J, DeVita V. The American Burkitt Lymphoma Registry: a progress report. Annals Of Internal Medicine 1975, 83: 31-6. PMID: 1147436, DOI: 10.7326/0003-4819-83-1-31.Peer-Reviewed Original ResearchConceptsLymphoma RegistryAfrican patientsAmerican patientsBurkitt's lymphomaEpstein-Barr virus titersPeripheral lymph node involvementAbrupt clinical presentationEpstein-Barr virus genomeHigh-dose cyclophosphamideLymph node involvementAmerican Burkitt's lymphomaCentral nervous systemPredominance of menPathologic reviewClinical presentationLymphocytic lymphomaAbsence of casesNonendemic regionsGastrointestinal tractNervous systemLymphomaPatientsVirus titersMore casesTime-space clustering
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply